
Indian Drugmakers Take Generic Semaglutide Battle to Overseas Markets
What Happened?
Indian pharmaceutical companies are expanding their generic semaglutide offerings internationally, with Dr Reddy's Laboratories and Sun Pharma among the early entrants. The domestic market faces increased competition and price erosion.
Key points
- Dr Reddy's Laboratories launched generic semaglutide in Canada and received Brazilian approval in November.
- Sun Pharma commercialized the drug in South Africa and Brazil.
- Hetero is exporting semaglutide to Africa, Asia, and the Middle East, targeting over 75 countries.
- Lupin has partnered with Galenicum to market semaglutide in 23 countries.
- Biocon and Ajanta Pharma are collaborating to supply the drug in 26 countries, with sales expected to start in FY28.
- Canada's GLP-1 market is valued at $2.6 billion, while Brazil's semaglutide market is around $245 million.
Key insights
- The international push may help Indian companies mitigate the impact of price erosion in the domestic market.
- Countries like Canada and Brazil represent significant opportunities due to their established demand for semaglutide.
- The competitive landscape varies, with Canada seeing slower generic uptake compared to Brazil's rapid shift to lower-priced alternatives.
Why it matters
The expansion into international markets could provide Indian drugmakers with new revenue streams amid domestic competition.
Entities
Source
Business Standard


